Status:
COMPLETED
Temocillin Versus Carbapenems for Urinary Tract Infection Due to ESBL-producing Enterobacteriaceae
Lead Sponsor:
Centre Hospitalier Annecy Genevois
Collaborating Sponsors:
APHP
Sorbonne University
Conditions:
Urinary Tract Infection Bacterial
Eligibility:
All Genders
18+ years
Brief Summary
To assess the efficacy of temocillin compared to carbapenems for the management of ESBL-E UTI.
Detailed Description
Adults with a definite diagnosis of ESBL-E UTI between January-2015 and October-2019 were enrolled in a multicenter retrospective case-control study. Cases were treated with temocillin ≥50% of the eff...
Eligibility Criteria
Inclusion
- Adults
- Diagnosis of UTI defined by at least two of the following symptoms :chills,temperature \>38°C (fever), flank or pelvic pain, nausea or vomiting, dysuria, urinary frequency, or urinary urgency, costovertebral angle tenderness on physical examination
- Positive urine culture with ≥ 103 CFU/mL of a single strain of ESBL-E
- Confirmed ESBL-producing enterobacteriaceae (ESBL-E) susceptible to carbapenems
Exclusion
- Multibacterial infection
- Opposition to data collection according to GDPR
Key Trial Info
Start Date :
January 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 31 2019
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT04671290
Start Date
January 1 2015
End Date
October 31 2019
Last Update
December 17 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.